259 completed. 259 Phase 2, 21 Phase 1, 9 Phase 3.
| Phase | Trials | Status |
|---|---|---|
| Phase 2 | 259 | Completed 259 |
| Phase 1 | 21 | Completed 21 |
| Phase 3 | 9 | Completed 9 |
Follow Psoriasis: new trials by email Literature Review of Psoriasis trials Research Report on Psoriasis
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| A Phase 2 Study of HB0017 in Psoriasis Patients HB0017 - Psoriasis (PsO) | Phase 2 | Completed | Huabo Biopharm Co., Ltd. | 206 | 2024-09-30 | 2026-10-23 |
| Proof of Concept Study of AX-158 in Patients With Mild to Moderate Plaque Psoriasis AX-158, Placebo - Psoriasis, Plaque Psoriasis | Phase 1 / Phase 2 | Completed | Artax Biopharma Inc | 31 | 2023-11-30 | 2025-10-03 |
| A Study to Evaluate Efficacy and Safety of SAR441566 in Adults With Plaque Psoriasis SAR441566, Placebo - Psoriasis | Phase 2 | Completed | Sanofi | 221 | 2023-10-26 | 2025-11-10 |
| To Evaluate the Efficacy and Safety of AK111 Injection in the Treatment of Moderate to Severe Plaque Psoriasis AK111 - Psoriasis, Skin Diseases | Phase 2 | Completed | Akeso | 454 | 2023-09-22 | 2025-01-23 |
| A Study of IBI112 in Chinese Patients With Psoriasis Who Were Previously Treated With Biologics regular treatment, Intensive treatment - Psoriasis | Phase 2 | Completed | Innovent Biologics (Suzhou) Co. Ltd. | 152 | 2023-08-28 | 2025-04-27 |
| Efficacy and Safety Study of HRO350 in Patients with Mild-to-moderate Psoriasis (the 'HeROPA' Study). HRO350, Placebo - Psoriasis | Phase 2 | Completed | Arctic Bioscience | 521 | 2023-05-25 | 2025-03-25 |
| A Study to Evaluate Effectiveness and Safety of BMS-986322 in Participants With Moderate-to-Severe Psoriasis BMS-986322, Placebo - Psoriasis | Phase 2 | Completed | Bristol-Myers Squibb | 109 | 2023-04-03 | 2025-11-25 |
| Chinese Medicine for Patients With Psoriasis Inflammatory skin disease formula, Placebo - Psoriasis | Phase 2 | Completed | Chinese University of Hong Kong | 60 | 2023-03-20 | 2026-07-27 |
| Roflumilast Versus Methotrexate in Psoriasis Roflumilast, Methotrexate - Psoriasis | Phase 2 / Phase 3 | Completed | Cairo University | 30 | 2023-01-09 | 2023-05-16 |
| Topical SGX302 for Mild-to-Moderate Psoriasis Hypericin - Psoriasis, Plaque Psoriasis | Phase 2 | Completed | Soligenix | 15 | 2022-12-14 | 2026-11-17 |
| Evaluation of Sonelokimab for the Treatment of Patients With Active Psoriatic Arthritis Sonelokimab, Placebo, Adalimumab - Arthritis, Psoriatic | Phase 2 | Completed | MoonLake Immunotherapeutics AG | 207 | 2022-12-13 | 2026-09-10 |
| Phase II Study Evaluating the Clinical Efficacy and Safety of GN-037 in Plaque Psoriasis GN-037, Clobetasol 17-propionate, Placebo - Psoriasis | Phase 2 | Completed | GEN İlaç ve Sağlık Ürünleri A.Ş. | 190 | 2022-12-07 | 2025-07-16 |
| High Dose Risankizumab for Psoriasis risankizumab - Psoriasis | Phase 2 | Completed | Oregon Medical Research Center | 20 | 2022-03-01 | 2025-10-24 |
| A Study to Evaluate the Efficacy, Safety, and Tolerability of NDI-034858 in Participants With Active Psoriatic Arthritis NDI-034858, Placebo - Psoriatic Arthritis | Phase 2 | Completed | Takeda | 305 | 2022-01-06 | 2024-05-31 |
| Study to Assess the Efficacy and Safety of Orismilast in Psoriasis Orismilast modified release tablets, Placebo - Psoriasis, Skin Diseases | Phase 2 | Completed | UNION therapeutics | 202 | 2021-12-30 | 2024-04-16 |
| A Study of Guselkumab and Golimumab Combination Therapy in Participants With Active Psoriatic Arthritis Guselkumab, Golimumab, Placebo - Arthritis, Psoriatic | Phase 2 | Completed | Janssen Research & Development, LLC | 91 | 2021-10-25 | 2026-07-23 |
| Study of the Effectiveness and Safety of SHR-1314 for Psoriatic Arthritis SHR-1314 injection, placebo - Psoriatic Arthritis | Phase 2 | Completed | Suzhou Suncadia Biopharmaceuticals Co., Ltd. | 112 | 2021-10-22 | 2024-12-12 |
| A Study to Evaluate IBI112 in the Treatment of Subjects With Moderate to Severe Plaque Psoriasis IBI112 dose 2, IBI112 dose 4, IBI112 dose 1 - Psoriasis | Phase 2 | Completed | Innovent Biologics (Suzhou) Co. Ltd. | 250 | 2021-09-23 | 2024-01-25 |
| A Proof-of-Activity Study With Orticumab in Subjects With Psoriasis and Cardiometabolic Risk Factors Orticumab, Placebo - Psoriasis, Inflammation | Phase 2 | Completed | Abcentra | 77 | 2021-06-30 | 2026-05-11 |
| A Dose-Ranging Phase II Study of AUR101 in Psoriasis (INDUS-3) AUR101, Placebo - Plaque Psoriasis | Phase 2 | Completed | Aurigene Discovery Technologies Limited | 141 | 2021-05-04 | 2022-12-13 |
Showing 20 of 259. Sign in to see all of them.
Arthritis, Psoriatic (33) · Skin Diseases (15) · Arthritis, Rheumatoid (8) · Arthritis (7) · Plaque, Amyloid (7) · Pruritus (6) · Lymphoma, Follicular (5) · Spondylitis, Ankylosing (5) · Bronchiolitis Obliterans Syndrome (4) · Inflammation (4) · Dermatitis, Atopic (3) · Eczema (3) · Osteoarthritis (3) · Autoimmune Diseases (2)
Skin Diseases, Papulosquamous (258) · Skin and Connective Tissue Diseases (257) · Skin Diseases (244) · Musculoskeletal Diseases (35) · Bone Diseases (34) · Joint Diseases (34) · Spinal Diseases (34) · Spondylitis (34) · Spondylarthritis (33) · Spondylarthropathies (33) · Arthritis (28) · Immune System Diseases (18) · Pathological Conditions, Signs and Symptoms (18) · Rheumatic Diseases (9)
Adalimumab (9) · apremilast (9) · calcipotriene (9) · bimekizumab (7) · secukinumab (7) · risankizumab (6) · Ustekinumab (5) · Etanercept (4) · Methotrexate (4) · Roflumilast (4) · guselkumab (4) · spesolimab (4) · Alefacept (3) · Betamethasone (3) · Calcitriol (3)
Pfizer (11) · Amgen (9) · Boehringer Ingelheim (8) · Novartis Pharmaceuticals (7) · Abbott (6) · Almirall, S.A. (6) · AbbVie (5) · GlaxoSmithKline (5) · UCB Biopharma SRL (5) · University of Medicine and Dentistry of New Jersey (5) · Bausch Health Americas, Inc. (4) · Galderma R&D (4) · Janssen Research & Development, LLC (4) · LEO Pharma (4) · National Institute of Arthritis and Musculoskeletal and Skin Diseases (NIAMS) (4)
United States (139) · Germany (59) · Canada (49) · Poland (35) · United Kingdom (20) · Japan (19) · Hungary (17) · Czechia (16) · Spain (16) · China (14) · Russia (14) · France (12) · Australia (11) · Bulgaria (11) · Denmark (11)
Binu J Alexander, MD (3) · Alice Gottlieb, MD, PhD (2) · Christoph Willers, MD (2) · Christoph Willers, MD, MBA (2)
PMID 35544084, PMID 19380660, PMID 30739254, PMID 31667790, PMID 35789257, PMID 35931879, PMID 36178584, PMID 37316690, PMID 37906417, PMID 40194794, PMID 40862624, PMID 41807031, PMID 12622624, PMID 12813013, PMID 12917302, PMID 15009298, PMID 15327535, PMID 15389187, PMID 15872205, PMID 15888152, PMID 16778789, PMID 16895558, PMID 17287478, PMID 17596167, PMID 18283176, PMID 18384439, PMID 19217154, PMID 19466961, PMID 19587341, PMID 19641206, PMID 19811850, PMID 20015525, PMID 20071701, PMID 20103558, PMID 20231202, PMID 20412573, PMID 20655127, PMID 20716226, PMID 20811392, PMID 21206136, PMID 21244768, PMID 21404914, PMID 21504485, PMID 21623773, PMID 21744074, PMID 22025784, PMID 22056790, PMID 22281165, PMID 22413944, PMID 22455413
2016 (9), 2018 (7), 2017 (6), 2014 (4), 2015 (3), 2023 (3), 2005 (2), 2008 (1), 2009 (1), 2019 (1), P60AR047782 (1), R33AR077495 (1), U44AI114473 (1)